EUVIMEDEUVIMED entdecken
Crossref

Switching from ranibizumab (0.5 mg) to brolucizumab (6 mg) in the management of wet age-related macular degeneration, reallife one year data

Libor Hejsek, Martina Rubesova, Lenka Havlickova

Archives of Clinical and Experimental Ophthalmology · 2023

DOI: 10.46439/ophthalmology.5.032 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Archives of Clinical and Experimental Ophthalmology, 2023. Verfasst von Libor Hejsek und 2 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Hejsek, L., Rubesova, M., & Havlickova, L. (2023). Switching from ranibizumab (0.5 mg) to brolucizumab (6 mg) in the management of wet age-related macular degeneration, reallife one year data. Archives of Clinical and Experimental Ophthalmology. https://doi.org/10.46439/ophthalmology.5.032

Vancouver

Hejsek L, Rubesova M, Havlickova L. Switching from ranibizumab (0.5 mg) to brolucizumab (6 mg) in the management of wet age-related macular degeneration, reallife one year data. Archives of Clinical and Experimental Ophthalmology. 2023. doi:10.46439/ophthalmology.5.032

BibTeX
@article{Hejsek2023,
  author = {Hejsek, Libor and Rubesova, Martina and Havlickova, Lenka},
  title = {Switching from ranibizumab (0.5 mg) to brolucizumab (6 mg) in the management of wet age-related macular degeneration, reallife one year data},
  journal = {Archives of Clinical and Experimental Ophthalmology},
  year = {2023},
  doi = {10.46439/ophthalmology.5.032}
}
Kostenlos starten →